Welcome to our dedicated page for Heartbeam SEC filings (Ticker: BEAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on portable ECG-based cardiac monitoring. These regulatory documents help investors and analysts understand how the company describes its business, technology, risks, and capital structure.
HeartBeam’s filings under the Securities Exchange Act of 1934 include, among others, current reports on Form 8-K. For example, an 8-K dated November 20, 2025 reports receipt of a Not Substantially Equivalent (NSE) letter from the U.S. Food and Drug Administration (FDA) related to the company’s 510(k) application for its 12-lead ECG synthesis software, and notes that the company stands behind its clinical data and intends to work with the FDA toward a resolution. The same filing confirms that HeartBeam’s common stock and warrants trade on NASDAQ under the symbols BEAT and BEATW and identifies the company as an emerging growth company.
On Stock Titan, HeartBeam’s SEC filings are updated in near real time as they are posted to the EDGAR system. Users can review annual and quarterly reports, when available, for detailed discussions of operating expenses, research and development activities, and liquidity, as well as risk factors related to regulatory approvals and commercialization of its cardiac monitoring technologies.
AI-powered tools on this page help explain complex filings by summarizing key points, highlighting material events, and pointing out items that may be important to investors, such as regulatory updates, capital raises, or changes in stockholders’ equity. Users can also quickly locate information about cleared indications for use of the HeartBeam System, descriptions of the 3D ECG and 12-lead synthesis technology, and references to the company’s patent portfolio as disclosed in its reports.
For those tracking insider and executive activity, Form 4 and related ownership filings, when available, can be used to monitor transactions in HeartBeam’s securities. Together, these documents offer a structured view of HeartBeam’s regulatory history, financial reporting, and significant corporate events.
HeartBeam, Inc. reported total assets of $5.98 million and combined cash and short-term investments of approximately $5.1 million as of June 30, 2025, with cash and equivalents of $3.26 million. The company recorded a net loss of $4.97 million for the quarter and $10.46 million for the six months ended June 30, 2025, and had an accumulated deficit of $66.73 million. Stockholders' equity was $4.18 million and shares outstanding increased to 34.02 million by June 30, 2025.
R&D expense rose year-to-date as product development and headcount increased while G&A declined. The company completed a February public offering that produced approximately $11.5 million in gross proceeds (about $10.3 million net) and issued shares under an ATM, leaving roughly $15.6 million available under that program. The HeartBeam System received FDA clearance on December 13, 2024; the company filed a 510(k) for its 12-lead synthesis software in January 2025, and its VALID-ECG pivotal study showed 93.4% diagnostic agreement. Management discloses substantial doubt about the company’s ability to continue as a going concern absent additional financing.